CPR Therapeutics Receives NSF Award

CPR Therapeutics Inc. (CPR-T), a start-up medical device company, announced today that it has received a National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I award for its project “A MULTIMODAL INTEGRATED SYSTEM FOR IMPROVED CARDIOPULMONARY RESUSCITATION” in the amount of $256K. The award is for a collaboration with The Johns Hopkins Hospital in Baltimore, MD.

CPR Therapeutics is developing multimodal cardiopulmonary resuscitation (CPR), a more effective form of automated mechanical CPR. Sudden cardiac arrest is the leading cause of death in western countries and there are currently no devices more effective than manual CPR. Intact survival after sudden cardiac arrest is below 10% in most communities.

Norman Paradis MD, CPR Therapeutics Founder and CEO said “We are excited to have received this validation of our efforts from one of the most prestigious scientific organizations in the world. The NSF has an extraordinary record of identifying and supporting innovations that eventually reach the bedside and improve patient outcomes.”

Henry Halperin MD, the company’s Chief Scientific Officer and a Professor of Cardiology at Johns Hopkins said “this support will significantly advance our ongoing preclinical development of multimodal CPR. In particular, it will allow us to focus on optimizing the synergies between the multiple pump mechanisms and refine the synchronization with electrical countershock.”

Studies supported by the award will begin immediately and will accelerate the company’s plan to commercialize an in-hospital version of its Vest-CPR System™.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”